A global, phase 3, randomized, double-blind study to evaluate safety and efficacy of selinexor, an XPO-1 inhibitor, in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis (XPORT-MF-034) Meeting Abstract
| Authors: | Maher, K.; Rampal, R. K.; Bose, P.; Podoltsev, N. A.; Harrison, C. N.; Hong, J.; Wang, X.; Chamoun, K.; Mascarenhas, J. |
| Abstract Title: | A global, phase 3, randomized, double-blind study to evaluate safety and efficacy of selinexor, an XPO-1 inhibitor, in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis (XPORT-MF-034) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 3209 |
| Language: | English |
| ACCESSION: | WOS:001159740303072 |
| DOI: | 10.1182/blood-2023-180695 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
